瑞康医药集团股份有限公司股票交易异常波动公告

Group 1 - The company's stock price experienced an abnormal fluctuation, with a cumulative closing price increase exceeding 20% over two consecutive trading days on December 3 and December 4, 2025 [2] - The company conducted a self-examination and verified with major stakeholders, confirming that there were no corrections or supplements needed for previously disclosed information [3] - The company did not find any recent media reports that could have significantly impacted its stock price [4] Group 2 - The company's operational situation remains normal, with no significant changes in its business environment [5] - There are no undisclosed major matters related to the company that should have been disclosed according to regulations [7] - The company confirmed that there were no violations of fair information disclosure regulations [6]